Author

F. Di Nicolantonio

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. Bardelli· 3 shared A. Bertotti· 2 shared A. Bartolini· 1 shared A. Gilmore· 1 shared A. Lorenzato· 1 shared A. M. McCorry· 1 shared A. Magri· 1 shared A. Sogari· 1 shared

Activity by Year

2017-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Bardelli

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer.

H. Khawaja, R. Briggs, C. Latimer, M. Rassel, D. Griffin, L. Hanson, A. Bardelli, F. Di Nicolantonio, S. S. McDade, C. J. Scott, S. Lambe, M. Maurya, A. U. Lindner, J. H. M. Prehn, J. Sousa, , S. Van Schaeybroeck

This study identifies Bcl-xL as a mediator of resistance to KRASG12C inhibitors in colorectal cancer and shows that combining Bcl-xL inhibition with KRASG12C inhibition enhances apoptosis and reduces tumor growth.

bioRxiv · May 10, 2022Cancer Biology

Drug-induced colorectal cancer persister cells show increased mutation rate

M. Russo, S. Pompei, A. Sogari, M. Corigliano, G. Crisafulli, A. Bertotti, M. Gherardi, F. Di Nicolantonio, A. Bardelli, M. C. Lagomarsino

The paper shows that drug treatment induces colorectal cancer persister cells with significantly increased mutation rates, suggesting new strategies to prevent tumor recurrence.

bioRxiv · May 17, 2021 · PreprintCancer Biology

Evolving neoantigen profiles in colorectal cancers with DNA repair defects

G. Rospo, A. Lorenzato, N. Amirouchene-Angelozzi, A. Magri, C. Cancelliere, G. Corti, C. Negrino, V. Amodio, M. Montone, A. Bartolini, L. Barault, L. Novara, C. Isella, E. Medico, A. Bertotti, , A. Bardelli

This study tracks neoantigen profiles in colorectal cancers with DNA repair defects, finding dynamic patterns linked to antigen presentation downregulation and evolvability.

bioRxiv · Jun 11, 2019Cancer Biology

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer

P. D. Dunne, H. G. Coleman, P. Bankhead, M. Alderdice, R. T. Gray, S. McQuaid, V. Bingham, M. B. Loughrey, J. A. James, A. M. McCorry, A. Gilmore, C. Holohan, D. Klingbiel, S. Tejpar, P. G. Johnston, , M. Lawler

The paper identifies Bcl-xL as a prognostic biomarker and predictor of response to adjuvant chemotherapy in BRAF-mutant stage II/III colon cancer using gene expression and immunohistochemistry validation.

bioRxiv · Oct 23, 2017Cancer Biology